US2014356355A1PendingUtilityA1
Il-17 receptor a antigen binding proteins

Assignee: AMGEN INCPriority: Oct 2, 2006Filed: Jun 13, 2014Published: Dec 4, 2014
Est. expiryOct 2, 2026(~0.2 yrs left)· nominal 20-yr term from priority
Inventors:Joel Tocker Jacques J. Peschon David Fitzpatrick James F. Smothers Christopher Mehlin Ai Ching Lim
A61P 5/16A61P 9/00A61P 5/38A61P 37/00A61P 31/14A61P 9/14A61P 37/08A61P 37/02A61P 9/10A61P 37/06A61P 3/10A61P 25/00A61P 3/00A61P 25/28A61P 29/00A61P 1/04A61P 1/00A61P 1/12A61P 1/16A61P 19/00A61P 19/02A61P 19/04A61P 17/10A61P 11/00A61P 11/06A61P 19/08A61P 17/00A61P 17/06A61P 21/00A61P 21/04A61K 2039/505C07K 2317/56C07K 2317/565C07K 2317/21C07K 16/2866C07K 2317/567C07K 2317/92A61K 2039/507A61K 39/3955A61K 45/06C07K 2317/76C07K 16/28A61K 39/395
PatentIndex Score
Cited by
References
Claims
Abstract

The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated antibody, comprising a human monoclonal antibody or IL-17 Receptor A binding fragment thereof that specifically binds IL-17 Receptor A and inhibits IL-17A from binding and activating said receptor. 
     
     
         2 . The antibody according to  claim 1 , wherein said antibody further inhibits IL-17F from binding and activating said receptor. 
     
     
         3 . The antibody according to  claim 1 , wherein said antibody is selected from the group consisting of:
 a. a humanized antibody;   b. a chimeric antibody;   c. a recombinant antibody;   d. a single chain antibody;   e. a diabody;   f. a triabody;   g. a tetrabody;   h. a Fab fragment;   i. a F(ab′)2 fragment;   j. an IgD antibody;   k. an IgE antibody;   l. an IgM antibody;   m. an IgG1 antibody;   n. an IgG2 antibody;   o. an IgG3 antibody; and   p. an IgG4 antibody.   
     
     
         4 . The antibody according to  claim 1 , wherein said antibody comprises an amino acid sequence selected from the group consisting of:
 A.
 a. a light chain variable domain sequence that is at least 80% identical to a light chain variable domain sequence of AM L 1-26 (SEQ ID NOs:27-53, respectively); 
 b. a heavy chain variable domain sequence that is at least 80% identical to a heavy chain variable domain sequence of AM H 1-26 (SEQ ID NOs:1-26, respectively); or 
 c. the light chain variable domain of (a) and the heavy chain variable domain of (b); and 
   B. a light chain CDR1, CDR2, CDR3 and a heavy chain CDR1, CDR2, CDR3 that differs by no more than a total of three amino acid additions, substitutions, and/or deletions in each CDR from the following sequences:
 a. a light chain CDR1 (SEQ ID NO:185), CDR2 (SEQ ID NO:186), CDR3 (SEQ ID NO:187) and a heavy chain CDR1 (SEQ ID NO:107), CDR2 (SEQ ID NO:108), CDR3 (SEQ ID NO:109) of antibody AM-1; 
 b. a light chain CDR1 (SEQ ID NO:188), CDR2 (SEQ ID NO:189), CDR3 (SEQ ID NO:190) and a heavy chain CDR1 (SEQ ID NO:110), CDR2 (SEQ ID NO:111), CDR3 (SEQ ID NO:112) of antibody AM-2; 
 c. a light chain CDR1 (SEQ ID NO:191), CDR2 (SEQ ID NO:192), CDR3 (SEQ ID NO:193) and a heavy chain CDR1 (SEQ ID NO:113), CDR2 (SEQ ID NO:114), CDR3 (SEQ TD NO:115) of antibody AM-3; 
 d. a light chain CDR1 (SEQ ID NO:194), CDR2 (SEQ ID NO:195), CDR3 (SEQ ID NO:196) and a heavy chain CDR1 (SEQ ID NO:116), CDR2 (SEQ ID NO:117), CDR3 (SEQ ID NO:118) of antibody AM-4; 
 e. a light chain CDR1 (SEQ ID NO:197), CDR2 (SEQ ID NO:198), CDR3 (SEQ ID NO:199) and a heavy chain CDR1 (SEQ ID NO:119), CDR2 (SEQ ID NO:120), CDR3 (SEQ ID NO:121) of antibody AM-5; 
 f. a light chain CDR1 (SEQ ID NO:200), CDR2 (SEQ ID NO:201), CDR3 (SEQ ID NO:202) and a heavy chain CDR1 (SEQ ID NO:122), CDR2 (SEQ ID NO:123), CDR3 (SEQ ID NO:124) of antibody AM-6; 
 g. a light chain CDR1 (SEQ ID NO:203), CDR2 (SEQ ID NO:204), CDR3 (SEQ ID NO:205) and a heavy chain CDR1 (SEQ ID NO:125), CDR2 (SEQ ID NO:126), CDR3 (SEQ ID NO:127) of antibody AM-7; 
 h. a light chain CDR1 (SEQ TD NO:206), CDR2 (SEQ TD NO:207), CDR3 (SEQ TD NO:208) and a heavy chain CDR1 (SEQ ID NO:128), CDR2 (SEQ ID NO:129), CDR3 (SEQ ID NO:130) of antibody AM-8; 
 i. a light chain CDR1 (SEQ TD NO:209), CDR2 (SEQ TD NO:210), CDR3 (SEQ ID NO:211) and a heavy chain CDR1 (SEQ ID NO:131), CDR2 (SEQ ID NO:132), CDR3 (SEQ ID NO:133) of antibody AM-9; 
 j. a light chain CDR1 (SEQ ID NO:212), CDR2 (SEQ ID NO:213), CDR3 (SEQ ID NO:214) and a heavy chain CDR1 (SEQ ID NO:134), CDR2 (SEQ ID NO:135), CDR3 (SEQ ID NO:136) of antibody AM-10; 
 k. a light chain CDR1 (SEQ ID NO:215), CDR2 (SEQ ID NO:216), CDR3 (SEQ ID NO:217) and a heavy chain CDR1 (SEQ ID NO:137), CDR2 (SEQ ID NO:138), CDR3 (SEQ ID NO:139) of antibody AM-11; 
 l. a light chain CDR1 (SEQ ID NO:218), CDR2 (SEQ ID NO:219), CDR3 (SEQ ID NO:220) and a heavy chain CDR1 (SEQ ID NO:140), CDR2 (SEQ ID NO:141), CDR3 (SEQ ID NO:142) of antibody AM-12; 
 m. a light chain CDR1 (SEQ ID NO:221), CDR2 (SEQ ID NO:222), CDR3 (SEQ ID NO:223) and a heavy chain CDR1 (SEQ ID NO:143), CDR2 (SEQ ID NO:144), CDR3 (SEQ ID NO:145) of antibody AM-13; 
 n. a light chain CDR1 (SEQ ID NO:224), CDR2 (SEQ ID NO:225), CDR3 (SEQ ID NO:226) and a heavy chain CDR1 (SEQ ID NO:146), CDR2 (SEQ ID NO:147), CDR3 (SEQ ID NO:148) of antibody AM-14; 
 o. a light chain CDR1 (SEQ ID NO:227), CDR2 (SEQ ID NO:228), CDR3 (SEQ ID NO:229) and a heavy chain CDR1 (SEQ ID NO:149), CDR2 (SEQ ID NO:150), CDR3 (SEQ ID NO:151) of antibody AM-15; 
 p. a light chain CDR1 (SEQ TD NO:230), CDR2 (SEQ TD NO:231), CDR3 (SEQ TD NO:232) and a heavy chain CDR1 (SEQ ID NO:152), CDR2 (SEQ ID NO:153), CDR3 (SEQ ID NO:154) of antibody AM-16; 
 q. a light chain CDR1 (SEQ ID NO:233), CDR2 (SEQ ID NO:234), CDR3 (SEQ ID NO:235) and a heavy chain CDR1 (SEQ ID NO:155), CDR2 (SEQ ID NO:156), CDR3 (SEQ ID NO:157) of antibody AM-17; 
 r. a light chain CDR1 (SEQ ID NO:236), CDR2 (SEQ ID NO:237), CDR3 (SEQ ID NO:238) and a heavy chain CDR1 (SEQ ID NO:158), CDR2 (SEQ ID NO:159), CDR3 (SEQ ID NO:160) of antibody AM-18; 
 s. a light chain CDR1 (SEQ ID NO:239), CDR2 (SEQ ID NO:240), CDR3 (SEQ ID NO:241) and a heavy chain CDR1 (SEQ ID NO:161), CDR2 (SEQ ID NO:162), CDR3 (SEQ ID NO:163) of antibody AM-19; 
 t. a light chain CDR1 (SEQ ID NO:242), CDR2 (SEQ ID NO:243), CDR3 (SEQ ID NO:244) and a heavy chain CDR1 (SEQ TD NO:164), CDR2 (SEQ TD NO:165), CDR3 (SEQ ID NO:166) of antibody AM-20; 
 u. a light chain CDR1 (SEQ ID NO:245), CDR2 (SEQ ID NO:246), CDR3 (SEQ ID NO:247) and a heavy chain CDR1 (SEQ TD NO:167), CDR2 (SEQ TD NO:168), CDR3 (SEQ ID NO:169) of antibody AM-21; 
 v. a light chain CDR1 (SEQ ID NO:248), CDR2 (SEQ ID NO:249), CDR3 (SEQ ID NO:250) and a heavy chain CDR1 (SEQ ID NO:170), CDR2 (SEQ ID NO:171), CDR3 (SEQ ID NO:172) of antibody AM-22; 
 w. a light chain CDR1 (SEQ ID NO:251), CDR2 (SEQ ID NO:252), CDR3 (SEQ ID NO:253) and a heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23; 
 x. a light chain CDR1 (SEQ ID NO:254), CDR2 (SEQ ID NO:255), CDR3 (SEQ ID NO:256) and a heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23; 
 y. a light chain CDR1 (SEQ ID NO:257), CDR2 (SEQ ID NO:258), CDR3 (SEQ ID NO:259) and a heavy chain CDR1 (SEQ ID NO:176), CDR2 (SEQ ID NO:177), CDR3 (SEQ ID NO:178) of antibody AM-24; 
 z. a light chain CDR1 (SEQ ID NO:260), CDR2 (SEQ ID NO:261), CDR3 (SEQ ID NO:262) and a heavy chain CDR1 (SEQ ID NO:179), CDR2 (SEQ ID NO:180), CDR3 (SEQ ID NO:181) of antibody AM-25; or 
 z.2. a light chain CDR1 (SEQ ID NO:263), CDR2 (SEQ ID NO:264), CDR3 (SEQ ID NO:265) and a heavy chain CDR1 (SEQ ID NO:182), CDR2 (SEQ ID NO:183), CDR3 (SEQ ID NO:184) of antibody AM-26; 
 wherein said antibody specifically binds TL-17 Receptor A. 
   
     
     
         5 . The antibody according to  claim 4 , wherein said antibody comprises an amino acid sequence selected from the group consisting of:
 a. a light chain variable domain and a heavy chain variable domain of AM L 1/AM H 1 (SEQ ID NO:27/SEQ ID NO:1);   b. a light chain variable domain and a heavy chain variable domain of AM L 2/AM H 2 (SEQ ID NO:28/SEQ ID NO:2);   c. a light chain variable domain and a heavy chain variable domain of AM L 3/AM H 3 (SEQ ID NO:29/SEQ ID NO:3);   d. a light chain variable domain and a heavy chain variable domain of AM L 4/AM H 4 (SEQ ID NO:30/SEQ ID NO:4);   e. a light chain variable domain and a heavy chain variable domain of AM L 5/AM H 5 (SEQ TD NO:31/SEQ ID NO:5);   f. a light chain variable domain and a heavy chain variable domain of AM L 6/AM H 6 (SEQ ID NO:32/SEQ ID NO:6)   g. a light chain variable domain and a heavy chain variable domain of AM L 7/AM H 7 (SEQ ID NO:33/SEQ ID NO:7);   h. a light chain variable domain and a heavy chain variable domain of AM L 8/AM H 8 (SEQ ID NO:34/SEQ ID NO:8);   i. a light chain variable domain and a heavy chain variable domain of AM L 9/AM H 9 (SEQ ID NO:35/SEQ ID NO:9);   j. a light chain variable domain and a heavy chain variable domain of AM L 10/AM H 10 (SEQ ID NO:36/SEQ ID NO:10);   k. a light chain variable domain and a heavy chain variable domain of AM L 11/AM H 11 (SEQ ID NO:37/SEQ ID NO:11);   l. a light chain variable domain and a heavy chain variable domain of AM L 12/AM H 12 (SEQ ID NO:38/SEQ ID NO:12);   m. a light chain variable domain and a heavy chain variable domain of AM L 13/AM H 13 (SEQ ID NO:39/SEQ ID NO:13);   n. a light chain variable domain and a heavy chain variable domain of AM L 14/AM H 14 (SEQ ID NO:40/SEQ ID NO:14);   o. a light chain variable domain and a heavy chain variable domain of AM L 15/AM H 15 (SEQ ID NO:41/SEQ ID NO:15);   p. a light chain variable domain and a heavy chain variable domain of AM L 16/AM H 16 (SEQ ID NO:42/SEQ ID NO:16);   q. a light chain variable domain and a heavy chain variable domain of AM L 17/AM H 17 (SEQ ID NO:43/SEQ ID NO:17);   r. a light chain variable domain and a heavy chain variable domain of AM L 18/AM H 18 (SEQ ID NO:44/SEQ ID NO:18);   s. a light chain variable domain and a heavy chain variable domain of AM L 19/AM H 19 (SEQ ID NO:45/SEQ ID NO:19);   t. a light chain variable domain and a heavy chain variable domain of AM L 20/AM H 20 (SEQ ID NO:46/SEQ ID NO:20);   u. a light chain variable domain and a heavy chain variable domain of AM L 21/AM H 21 (SEQ ID NO:47/SEQ ID NO:21);   v. a light chain variable domain and a heavy chain variable domain of AM L 22/AM H 22 (SEQ ID NO:48/SEQ ID NO:22);   w. a light chain variable domain and a heavy chain variable domain of AM L 23/AM H 23 (SEQ ID NO: 49 or SEQ ID NO:50/SEQ TD NO:23);   x. a light chain variable domain and a heavy chain variable domain of AM L 24/AM H 24 (SEQ ID NO:51/SEQ ID NO:24);   y. a light chain variable domain and a heavy chain variable domain of AM L 25/AM H 25 (SEQ ID NO:52/SEQ ID NO:25); and   z. a light chain variable domain and a heavy chain variable domain of AM L 26/AM H 26 (SEQ ID NO:53/SEQ ID NO:26);   wherein said antibody specifically binds IL-17 Receptor A.   
     
     
         6 . The antibody according to  claim 4 , wherein said antibody comprises an amino acid sequence selected from the group consisting of:
 a. a light chain CDR1 (SEQ ID NO:185), CDR2 (SEQ ID NO:186), CDR3 (SEQ ID NO:187) and a heavy chain CDR1 (SEQ ID NO:107), CDR2 (SEQ ID NO:108), CDR3 (SEQ ID NO:109) of antibody AM-1;   b. a light chain CDR1 (SEQ ID NO:188), CDR2 (SEQ ID NO:189), CDR3 (SEQ ID NO:190) and a heavy chain CDR1 (SEQ ID NO:110), CDR2 (SEQ ID NO:111), CDR3 (SEQ ID NO:112) of antibody AM-2;   c. a light chain CDR1 (SEQ ID NO:191), CDR2 (SEQ ID NO:192), CDR3 (SEQ ID NO:193) and a heavy chain CDR1 (SEQ ID NO:113), CDR2 (SEQ ID NO:114), CDR3 (SEQ ID NO:115) of antibody AM-3;   d. a light chain CDR1 (SEQ ID NO:194), CDR2 (SEQ ID NO:195), CDR3 (SEQ ID NO:196) and a heavy chain CDR1 (SEQ ID NO:116), CDR2 (SEQ ID NO:117), CDR3 (SEQ ID NO:118) of antibody AM-4;   e. a light chain CDR 1 (SEQ TD NO:197), CDR2 (SEQ TD NO:198), CDR3 (SEQ TD NO:199) and a heavy chain CDR1 (SEQ ID NO:119), CDR2 (SEQ ID NO:120), CDR3 (SEQ ID NO:121) of antibody AM-5;   f. a light chain CDR1 (SEQ ID NO:200), CDR2 (SEQ ID NO:201), CDR3 (SEQ ID NO:202) and a heavy chain CDR1 (SEQ ID NO:122), CDR2 (SEQ ID NO:123), CDR3 (SEQ ID NO:124) of antibody AM-6;   g. a light chain CDR1 (SEQ ID NO:203), CDR2 (SEQ ID NO:204), CDR3 (SEQ ID NO:205) and a heavy chain CDR1 (SEQ ID NO:125), CDR2 (SEQ ID NO:126), CDR3 (SEQ ID NO:127) of antibody AM-7;   h. a light chain CDR1 (SEQ ID NO:206), CDR2 (SEQ ID NO:207), CDR3 (SEQ ID NO:208) and a heavy chain CDR1 (SEQ ID NO:128), CDR2 (SEQ ID NO:129), CDR3 (SEQ ID NO:130) of antibody AM-8;   i. a light chain CDR1 (SEQ ID NO:209), CDR2 (SEQ ID NO:210), CDR3 (SEQ ID NO:211) and a heavy chain CDR1 (SEQ TD NO:131), CDR2 (SEQ TD NO:132), CDR3 (SEQ ID NO:133) of antibody AM-9;   j. a light chain CDR1 (SEQ ID NO:212), CDR2 (SEQ ID NO:213), CDR3 (SEQ ID NO:214) and a heavy chain CDR1 (SEQ TD NO:134), CDR2 (SEQ TD NO:135), CDR3 (SEQ ID NO:136) of antibody AM-10;   k. a light chain CDR1 (SEQ ID NO:215), CDR2 (SEQ ID NO:216), CDR3 (SEQ ID NO:217) and a heavy chain CDR1 (SEQ ID NO:137), CDR2 (SEQ ID NO:138), CDR3 (SEQ ID NO:139) of antibody AM-11;   l. a light chain CDR1 (SEQ ID NO:218), CDR2 (SEQ ID NO:219), CDR3 (SEQ ID NO:220) and a heavy chain CDR1 (SEQ ID NO:140), CDR2 (SEQ ID NO:141), CDR3 (SEQ ID NO:142) of antibody AM-12;   m. a light chain CDR1 (SEQ ID NO:221), CDR2 (SEQ ID NO:222), CDR3 (SEQ ID NO:223) and a heavy chain CDR1 (SEQ ID NO:143), CDR2 (SEQ ID NO:144), CDR3 (SEQ ID NO:145) of antibody AM-13;   n. a light chain CDR1 (SEQ ID NO:224), CDR2 (SEQ ID NO:225), CDR3 (SEQ ID NO:226) and a heavy chain CDR1 (SEQ ID NO:146), CDR2 (SEQ ID NO:147), CDR3 (SEQ ID NO:148) of antibody AM-14;   o. a light chain CDR1 (SEQ ID NO:227), CDR2 (SEQ ID NO:228), CDR3 (SEQ ID NO:229) and a heavy chain CDR1 (SEQ ID NO:149), CDR2 (SEQ ID NO:150), CDR3 (SEQ ID NO:151) of antibody AM-15;   p. a light chain CDR1 (SEQ ID NO:230), CDR2 (SEQ ID NO:231), CDR3 (SEQ ID NO:232) and a heavy chain CDR1 (SEQ ID NO:152), CDR2 (SEQ ID NO:153), CDR3 (SEQ ID NO:154) of antibody AM-16;   q. a light chain CDR1 (SEQ TD NO:233), CDR2 (SEQ TD NO:234), CDR3 (SEQ TD NO:235) and a heavy chain CDR1 (SEQ ID NO:155), CDR2 (SEQ ID NO:156), CDR3 (SEQ ID NO:157) of antibody AM-17;   r. a light chain CDR1 (SEQ ID NO:236), CDR2 (SEQ ID NO:237), CDR3 (SEQ ID NO:238) and a heavy chain CDR1 (SEQ ID NO:158), CDR2 (SEQ ID NO:159), CDR3 (SEQ ID NO:160) of antibody AM-18;   s. a light chain CDR1 (SEQ ID NO:239), CDR2 (SEQ ID NO:240), CDR3 (SEQ ID NO:241) and a heavy chain CDR1 (SEQ ID NO:161), CDR2 (SEQ ID NO:162), CDR3 (SEQ ID NO:163) of antibody AM-19;   t. a light chain CDR1 (SEQ ID NO:242), CDR2 (SEQ ID NO:243), CDR3 (SEQ ID NO:244) and a heavy chain CDR1 (SEQ ID NO:164), CDR2 (SEQ ID NO:165), CDR3 (SEQ ID NO:166) of antibody AM-20;   u. a light chain CDR1 (SEQ ID NO:245), CDR2 (SEQ ID NO:246), CDR3 (SEQ ID NO:247) and a heavy chain CDR1 (SEQ TD NO:167), CDR2 (SEQ TD NO:168), CDR3 (SEQ ID NO:169) of antibody AM-21;   v. a light chain CDR1 (SEQ ID NO:248), CDR2 (SEQ ID NO:249), CDR3 (SEQ ID NO:250) and a heavy chain CDR1 (SEQ TD NO:170), CDR2 (SEQ TD NO:171), CDR3 (SEQ ID NO:172) of antibody AM-22;   w. a light chain CDR1 (SEQ ID NO:251), CDR2 (SEQ ID NO:252), CDR3 (SEQ ID NO:253) and a heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23;   x. a light chain CDR1 (SEQ ID NO:254), CDR2 (SEQ ID NO:255), CDR3 (SEQ ID NO:256) and a heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23;   y. a light chain CDR1 (SEQ ID NO:257), CDR2 (SEQ ID NO:258), CDR3 (SEQ ID NO:259) and a heavy chain CDR1 (SEQ ID NO:176), CDR2 (SEQ ID NO:177), CDR3 (SEQ ID NO:178) of antibody AM-24;   z. a light chain CDR1 (SEQ ID NO:260), CDR2 (SEQ ID NO:261), CDR3 (SEQ ID NO:262) and a heavy chain CDR1 (SEQ ID NO:179), CDR2 (SEQ ID NO:180), CDR3 (SEQ ID NO:181) of antibody AM-25; or   z.2. a light chain CDR1 (SEQ ID NO:263), CDR2 (SEQ ID NO:264), CDR3 (SEQ ID NO:265) and a heavy chain CDR1 (SEQ ID NO:182), CDR2 (SEQ ID NO:183), CDR3 (SEQ ID NO:184) of antibody AM-26;   wherein said antibody specifically binds IL-17 Receptor A.   
     
     
         7 . The antibody according to  claim 1 , or an IL-17 Receptor A binding fragment thereof, comprising
 a. a heavy chain CDR1 comprising an amino acid sequence selected from the group consisting of:
 i. X 1 YGIS, wherein X 1  is selected from the group consisting of R, S and G; 
   b. a heavy chain CDR2 comprising an amino acid sequence selected from the group consisting of:
 i. WISX 1 YX 2 GNTX 3 YAQX 4 X 5 QG, wherein X 1  is selected from the group consisting of A, X 2  is selected from the group consisting of N, S and K, X 3  is selected from the group consisting of N and K, X 4  is selected from the group consisting of K and N, and X 5  is selected from the group consisting of L and F; 
   c. a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of:
 i. X 1 QLX 2 X 3 DY, wherein X 1  is selected from the group consisting of R and K, X 2  is selected from the group consisting of Y, V, and A, and X 3  is selected from the group consisting of F and L; 
 ii. X 1 QLX 2 FDY, wherein X 1  is selected from the group consisting of R and K, and X 2  is selected from the group consisting of Y and V; 
   d. a light chain CDR1 comprising an amino acid sequence selected from the group consisting of:
 i. RASQSX 1 X 2 X 3 X 4 LA, wherein X 1  is selected from the group consisting of V and I, X 2  is selected from the group consisting of I and S, X 3  is selected from the group consisting of S and T, X 4  is selected from the group consisting of N and S, and X 5  is selected from the group consisting of A and N, and 
 ii. RASQSX 1 SSNLA, wherein X 1  is selected from the group consisting of V and I; 
   e. a light chain CDR2 comprising an amino acid sequence selected from the group consisting of:
 i. X 1 X 2 STRAX 3 , wherein X 1  is selected from the group consisting of G and D, X 2  is selected from the group consisting of A and T, and X 3  is selected from the group consisting of T and A, and 
 ii. X 1 ASTRAX 2 , wherein X 1  is selected from the group consisting of G and D, and X 2  is selected from the group consisting of A and T; and 
   f. a light chain CDR3 comprising an amino acid sequence selected from the group consisting of:
 i. QQYDX 1 WPLT, wherein X 1  is selected from the group consisting of N, T, and I;
 wherein said antibody binds IL-17 Receptor A. 
 
   
     
     
         8 . The antibody according to  claim 1 , wherein the antibody is formulated as a pharmaceutical composition. 
     
     
         9 . An isolated polynucleotide, comprising a polynucleotide that encodes an amino acid sequence comprising the amino acid sequence of  claim 4 . 
     
     
         10 . The isolated polynucleotide according to  claim 9 , wherein the polynucleotide is contained within a plasmid. 
     
     
         11 . The plasmid according to  claim 10 , wherein said plasmid is an expression vector. 
     
     
         12 . The expression vector according to  claim 11 , wherein said expression vector is contained within a cell and wherein said cell is selected from the group consisting of:
 a. a prokaryotic cell;   b. a eukaryotic cell;   c. a mammalian cell;   d. an insect cell; and   e. a CHO cell.   
     
     
         13 . An isolated monoclonal antibody, or IL-17 Receptor A-binding fragment thereof, comprising an isolated monoclonal antibody that binds to human IL-17 Receptor A and that competes for binding with an antibody selected from the group consisting of
 A. an isolated antibody comprising
 a. a light chain CDR1 (SEQ ID NO:188), CDR2 (SEQ ID NO:189), CDR3 (SEQ ID NO:190) and a heavy chain CDR1 (SEQ ID NO:110), CDR2 (SEQ ID NO:111), CDR3 (SEQ ID NO:112) of antibody AM-2; 
 b. a light chain CDR1 (SEQ ID NO:191), CDR2 (SEQ ID NO:192), CDR3 (SEQ ID NO:193) and a heavy chain CDR1 (SEQ ID NO:113), CDR2 (SEQ ID NO:114), CDR3 (SEQ ID NO:115) of antibody AM-3; 
 c. a light chain CDR1 (SEQ ID NO:197), CDR2 (SEQ ID NO:198), CDR3 (SEQ ID NO:199) and a heavy chain CDR1 (SEQ TD NO:119), CDR2 (SEQ TD NO:120), CDR3 (SEQ ID NO:121) of antibody AM-5; 
 d. a light chain CDR1 (SEQ ID NO:209), CDR2 (SEQ ID NO:210), CDR3 (SEQ ID NO:211) and a heavy chain CDR1 (SEQ ID NO:131), CDR2 (SEQ ID NO:132), CDR3 (SEQ ID NO:133) of antibody AM-9; 
 e. a light chain CDR1 (SEQ ID NO:212), CDR2 (SEQ ID NO:213), CDR3 (SEQ ID NO:214) and a heavy chain CDR1 (SEQ ID NO:134), CDR2 (SEQ ID NO:135), CDR3 (SEQ ID NO:136) of antibody AM-10; 
 f. a light chain CDR1 (SEQ ID NO:218), CDR2 (SEQ ID NO:219), CDR3 (SEQ ID NO:220) and a heavy chain CDR1 (SEQ ID NO:140), CDR2 (SEQ ID NO:141), CDR3 (SEQ ID NO:142) of antibody AM-12; 
 g. a light chain CDR1 (SEQ ID NO:224), CDR2 (SEQ ID NO:225), CDR3 (SEQ ID NO:226) and a heavy chain CDR1 (SEQ ID NO:146), CDR2 (SEQ ID NO:147), CDR3 (SEQ TD NO:148) of antibody AM-14; 
 h. a light chain CDR1 (SEQ ID NO:227), CDR2 (SEQ ID NO:228), CDR3 (SEQ ID NO:229) and a heavy chain CDR1 (SEQ ID NO:149), CDR2 (SEQ ID NO:150), CDR3 (SEQ TD NO:151) of antibody AM-15; 
 i. a light chain CDR1 (SEQ ID NO:230), CDR2 (SEQ ID NO:231), CDR3 (SEQ ID NO:232) and a heavy chain CDR1 (SEQ ID NO:152), CDR2 (SEQ ID NO:153), CDR3 (SEQ ID NO:154) of antibody AM-16; 
 j. a light chain CDR1 (SEQ ID NO:233), CDR2 (SEQ ID NO:234), CDR3 (SEQ ID NO:235) and a heavy chain CDR1 (SEQ ID NO:155), CDR2 (SEQ ID NO:156), CDR3 (SEQ ID NO:157) of antibody AM-17; 
 k. a light chain CDR1 (SEQ ID NO:239), CDR2 (SEQ ID NO:240), CDR3 (SEQ ID NO:241) and a heavy chain CDR1 (SEQ ID NO:161), CDR2 (SEQ ID NO:162), CDR3 (SEQ ID NO:163) of antibody AM-19; 
 l. a light chain CDR1 (SEQ ID NO:242), CDR2 (SEQ ID NO:243), CDR3 (SEQ ID NO:244) and a heavy chain CDR1 (SEQ ID NO:164), CDR2 (SEQ ID NO:165), CDR3 (SEQ ID NO:166) of antibody AM-20; 
 m. a light chain CDR1 (SEQ ID NO:245), CDR2 (SEQ ID NO:246), CDR3 (SEQ ID NO:247) and a heavy chain CDR1 (SEQ ID NO:167), CDR2 (SEQ ID NO:168), CDR3 (SEQ ID NO:169) of antibody AM-21; 
 n. a light chain CDR1 (SEQ ID NO:248), CDR2 (SEQ ID NO:249), CDR3 (SEQ ID NO:250) and a heavy chain CDR1 (SEQ ID NO:170), CDR2 (SEQ ID NO:171), CDR3 (SEQ ID NO:172) of antibody AM-22; 
 o. a light chain CDR1 (SEQ TD NO:251), CDR2 (SEQ TD NO:252), CDR3 (SEQ TD NO:253) and a heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23; 
 p. a light chain CDR1 (SEQ ID NO:254), CDR2 (SEQ ID NO:255), CDR3 (SEQ ID NO:256) and a heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23; 
 q. a light chain CDR1 (SEQ ID NO:257), CDR2 (SEQ ID NO:258), CDR3 (SEQ ID NO:259) and a heavy chain CDR1 (SEQ ID NO:176), CDR2 (SEQ ID NO:177), CDR3 (SEQ ID NO:178) of antibody AM-24; 
 r. a light chain CDR1 (SEQ ID NO:260), CDR2 (SEQ ID NO:261), CDR3 (SEQ ID NO:262) and a heavy chain CDR1 (SEQ ID NO:179), CDR2 (SEQ ID NO:180), CDR3 (SEQ ID NO:181) of antibody AM-25; 
 wherein said antibody specifically binds to IL-17 Receptor A; and 
   B. an isolated antibody comprising
 a. a light chain variable domain and a heavy chain variable domain of AM L 2/AM H 2 (SEQ TD NO:28/SEQ ID NO:2); 
 b. a light chain variable domain and a heavy chain variable domain of AM L 3/AM H 3 (SEQ ID NO:29/SEQ ID NO:3); 
 c. a light chain variable domain and a heavy chain variable domain of AM L 5/AM H 5 (SEQ ID NO:31/SEQ ID NO:5); 
 d. a light chain variable domain and a heavy chain variable domain of AM L 9/AM H 9 (SEQ ID NO:35/SEQ ID NO:9); 
 e. a light chain variable domain and a heavy chain variable domain of AM L 10/AM H 10 (SEQ ID NO:36/SEQ ID NO:10); 
 f. a light chain variable domain and a heavy chain variable domain of AM L 12/AM H 12 (SEQ ID NO:38/SEQ ID NO:12); 
 g. a light chain variable domain and a heavy chain variable domain of AM L 14/AM H 14 (SEQ ID NO:40/SEQ ID NO:14); 
 h. a light chain variable domain and a heavy chain variable domain of AM L 15/AM H 15 (SEQ ID NO:41/SEQ ID NO:15); 
 i. a light chain variable domain and a heavy chain variable domain of AM L 16/AM H 16 (SEQ ID NO:42/SEQ ID NO:16); 
 j. a light chain variable domain and a heavy chain variable domain of AM L 17/AM H 17 (SEQ ID NO:43/SEQ ID NO:17); 
 k. a light chain variable domain and a heavy chain variable domain of AM L 19/AM H 19 (SEQ ID NO:45/SEQ ID NO:19); 
 l. a light chain variable domain and a heavy chain variable domain of AM L 20/AM H 20 (SEQ ID NO:46/SEQ ID NO:20); 
 m. a light chain variable domain and a heavy chain variable domain of AM L 21/AM H 21 (SEQ ID NO:47/SEQ ID NO:21); 
 n. a light chain variable domain and a heavy chain variable domain of AM L 22/AM H 22 (SEQ ID NO:48/SEQ ID NO:22); 
 o. a light chain variable domain and a heavy chain variable domain of AM L 23/AM H 23 (SEQ ID NO:49 or SEQ ID NO:50/SEQ ID NO:23); 
 p. a light chain variable domain and a heavy chain variable domain of AM L 24/AM H 24 (SEQ ID NO:51/SEQ ID NO:24); and 
 q. a light chain variable domain and a heavy chain variable domain of AM L 25/AM H 25 (SEQ ID NO:52/SEQ ID NO:25). 
   
     
     
         14 . A method of treating a disease state associated with TL-17 Receptor A activation in a patient in need thereof, comprising administering to said patient a composition comprising an antibody that specifically binds IL-17 Receptor A and inhibits the binding of IL-17A, wherein said antibody is selected from the group consisting of:
 A. an isolated antibody, or IL-17 Receptor A-binding fragment thereof, comprising
 a. a light chain variable domain sequence that is at least 80% identical to a light chain variable domain sequence of AM L 1-26 (SEQ ID NOs:27-53, respectively); 
 b. a heavy chain variable domain sequence that is at least 80% identical to a heavy chain variable domain sequence of AM H 1-26 (SEQ ID NOs:1-26, respectively); 
 c. the light chain variable domain of (a) and the heavy chain variable domain of (b); 
   wherein said antibody specifically binds to IL-17 Receptor A;   B. an isolated antibody, or IL-17 Receptor A-binding fragment thereof, comprising
 a. a light chain CDR1 (SEQ ID NO:185), CDR2 (SEQ ID NO:186), CDR3 (SEQ ID NO:187) and a heavy chain CDR1 (SEQ ID NO:107), CDR2 (SEQ ID NO:108), CDR3 (SEQ ID NO:109) of antibody AM-1; 
 b. a light chain CDR1 (SEQ ID NO:188), CDR2 (SEQ ID NO:189), CDR3 (SEQ ID NO:190) and a heavy chain CDR1 (SEQ ID NO:110), CDR2 (SEQ ID NO:111), CDR3 (SEQ ID NO:112) of antibody AM-2; 
 c. a light chain CDR1 (SEQ ID NO:191), CDR2 (SEQ ID NO:192), CDR3 (SEQ ID NO:193) and a heavy chain CDR1 (SEQ ID NO:113), CDR2 (SEQ ID NO:114), CDR3 (SEQ ID NO:115) of antibody AM-3; 
 d. a light chain CDR1 (SEQ ID NO:194), CDR2 (SEQ ID NO:195), CDR3 (SEQ ID NO:196) and a heavy chain CDR1 (SEQ ID NO:116), CDR2 (SEQ ID NO:117), CDR3 (SEQ TD NO:118) of antibody AM-4; 
 e. a light chain CDR1 (SEQ ID NO:197), CDR2 (SEQ ID NO:198), CDR3 (SEQ ID NO:199) and a heavy chain CDR1 (SEQ ID NO:119), CDR2 (SEQ ID NO:120), CDR3 (SEQ ID NO:121) of antibody AM-5; 
 f. a light chain CDR1 (SEQ ID NO:200), CDR2 (SEQ ID NO:201), CDR3 (SEQ ID NO:202) and a heavy chain CDR1 (SEQ ID NO:122), CDR2 (SEQ ID NO:123), CDR3 (SEQ ID NO:124) of antibody AM-6; 
 g. a light chain CDR1 (SEQ ID NO:203), CDR2 (SEQ ID NO:204), CDR3 (SEQ ID NO:205) and a heavy chain CDR1 (SEQ ID NO:125), CDR2 (SEQ ID NO:126), CDR3 (SEQ ID NO:127) of antibody AM-7; 
 h. a light chain CDR1 (SEQ ID NO:206), CDR2 (SEQ ID NO:207), CDR3 (SEQ ID NO:208) and a heavy chain CDR1 (SEQ ID NO:128), CDR2 (SEQ ID NO:129), CDR3 (SEQ ID NO:130) of antibody AM-8; 
 i. a light chain CDR1 (SEQ TD NO:209), CDR2 (SEQ TD NO:210), CDR3 (SEQ ID NO:211) and a heavy chain CDR1 (SEQ ID NO:131), CDR2 (SEQ ID NO:132), CDR3 (SEQ ID NO:133) of antibody AM-9; 
 j. a light chain CDR1 (SEQ TD NO:212), CDR2 (SEQ TD NO:213), CDR3 (SEQ ID NO:214) and a heavy chain CDR1 (SEQ ID NO:134), CDR2 (SEQ ID NO:135), CDR3 (SEQ ID NO:136) of antibody AM-10; 
 k. a light chain CDR1 (SEQ ID NO:215), CDR2 (SEQ ID NO:216), CDR3 (SEQ ID NO:217) and a heavy chain CDR1 (SEQ ID NO:137), CDR2 (SEQ ID NO:138), CDR3 (SEQ ID NO:139) of antibody AM-11; 
 l. a light chain CDR1 (SEQ ID NO:218), CDR2 (SEQ ID NO:219), CDR3 (SEQ ID NO:220) and a heavy chain CDR1 (SEQ ID NO:140), CDR2 (SEQ ID NO:141), CDR3 (SEQ ID NO:142) of antibody AM-12; 
 m. a light chain CDR1 (SEQ ID NO:221), CDR2 (SEQ ID NO:222), CDR3 (SEQ ID NO:223) and a heavy chain CDR1 (SEQ ID NO:143), CDR2 (SEQ ID NO:144), CDR3 (SEQ ID NO:145) of antibody AM-13; 
 n. a light chain CDR1 (SEQ ID NO:224), CDR2 (SEQ ID NO:225), CDR3 (SEQ ID NO:226) and a heavy chain CDR1 (SEQ ID NO:146), CDR2 (SEQ ID NO:147), CDR3 (SEQ ID NO:148) of antibody AM-14; 
 o. a light chain CDR1 (SEQ ID NO:227), CDR2 (SEQ ID NO:228), CDR3 (SEQ ID NO:229) and a heavy chain CDR1 (SEQ ID NO:149), CDR2 (SEQ ID NO:150), CDR3 (SEQ ID NO:151) of antibody AM-15; 
 p. a light chain CDR1 (SEQ ID NO:230), CDR2 (SEQ ID NO:231), CDR3 (SEQ ID NO:232) and a heavy chain CDR1 (SEQ ID NO:152), CDR2 (SEQ ID NO:153), CDR3 (SEQ ID NO:154) of antibody AM-16; 
 q. a light chain CDR1 (SEQ TD NO:233), CDR2 (SEQ TD NO:234), CDR3 (SEQ TD NO:235) and a heavy chain CDR1 (SEQ ID NO:155), CDR2 (SEQ ID NO:156), CDR3 (SEQ ID NO:157) of antibody AM-17; 
 r. a light chain CDR1 (SEQ ID NO:236), CDR2 (SEQ ID NO:237), CDR3 (SEQ ID NO:238) and a heavy chain CDR1 (SEQ ID NO:158), CDR2 (SEQ ID NO:159), CDR3 (SEQ ID NO:160) of antibody AM-18; 
 s. a light chain CDR1 (SEQ ID NO:239), CDR2 (SEQ ID NO:240), CDR3 (SEQ ID NO:241) and a heavy chain CDR1 (SEQ ID NO:161), CDR2 (SEQ ID NO:162), CDR3 (SEQ ID NO:163) of antibody AM-19; 
 t. a light chain CDR1 (SEQ ID NO:242), CDR2 (SEQ ID NO:243), CDR3 (SEQ ID NO:244) and a heavy chain CDR1 (SEQ ID NO:164), CDR2 (SEQ ID NO:165), CDR3 (SEQ ID NO:166) of antibody AM-20; 
 u. a light chain CDR1 (SEQ ID NO:245), CDR2 (SEQ ID NO:246), CDR3 (SEQ ID NO:247) and a heavy chain CDR1 (SEQ TD NO:167), CDR2 (SEQ TD NO:168), CDR3 (SEQ ID NO:169) of antibody AM-21; 
 v. a light chain CDR1 (SEQ ID NO:248), CDR2 (SEQ ID NO:249), CDR3 (SEQ ID NO:250) and a heavy chain CDR1 (SEQ TD NO:170), CDR2 (SEQ TD NO:171), CDR3 (SEQ ID NO:172) of antibody AM-22; 
 w. a light chain CDR1 (SEQ ID NO:251), CDR2 (SEQ ID NO:252), CDR3 (SEQ ID NO:253) and a heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23; 
 x. a light chain CDR1 (SEQ ID NO:254), CDR2 (SEQ ID NO:255), CDR3 (SEQ ID NO:256) and a heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23; 
 y. a light chain CDR1 (SEQ ID NO:257), CDR2 (SEQ ID NO:258), CDR3 (SEQ ID NO:259) and a heavy chain CDR1 (SEQ ID NO:176), CDR2 (SEQ ID NO:177), CDR3 (SEQ ID NO:178) of antibody AM-24; 
 z. a light chain CDR1 (SEQ ID NO:260), CDR2 (SEQ ID NO:261), CDR3 (SEQ ID NO:262) and a heavy chain CDR1 (SEQ ID NO:179), CDR2 (SEQ ID NO:180), CDR3 (SEQ ID NO:181) of antibody AM-25; 
 z.2. a light chain CDR1 (SEQ ID NO:263), CDR2 (SEQ ID NO:264), CDR3 (SEQ ID NO:265) and a heavy chain CDR1 (SEQ ID NO:182), CDR2 (SEQ ID NO:183), CDR3 (SEQ ID NO:184) of antibody AM-26; 
 wherein said antibody specifically binds to IL-17 Receptor A; and 
   C. an isolated antibody, or IL-17 Receptor A-binding fragment thereof, comprising
 a. a light chain variable domain and a heavy chain variable domain of AM L 1/AM H 1 (SEQ ID NO:27/SEQ ID NO:1); 
 b. a light chain variable domain and a heavy chain variable domain of AM L 2/AM H 2 (SEQ ID NO:28/SEQ ID NO:2); 
 c. a light chain variable domain and a heavy chain variable domain of AM L 3/AM H 3 (SEQ ID NO:29/SEQ ID NO:3); 
 d. a light chain variable domain and a heavy chain variable domain of AM L 4/AM H 4 (SEQ ID NO:30/SEQ ID NO:4); 
 e. a light chain variable domain and a heavy chain variable domain of AM L 5/AM H 5 (SEQ ID NO:31/SEQ ID NO:5); 
 f. a light chain variable domain and a heavy chain variable domain of AM L 6/AM H 6 (SEQ ID NO:32/SEQ ID NO:6) 
 g. a light chain variable domain and a heavy chain variable domain of AM L 7/AM H 7 (SEQ TD NO:33/SEQ ID NO:7); 
 h. a light chain variable domain and a heavy chain variable domain of AM L 8/AM H 8 (SEQ ID NO:34/SEQ ID NO:8); 
 i. a light chain variable domain and a heavy chain variable domain of AM L 9/AM H 9 (SEQ ID NO:35/SEQ ID NO:9); 
 j. a light chain variable domain and a heavy chain variable domain of AM L 10/AM H 10 (SEQ ID NO:36/SEQ ID NO:10); 
 k. a light chain variable domain and a heavy chain variable domain of AM L 11/AM H 11 (SEQ ID NO:37/SEQ ID NO:11); 
 l. a light chain variable domain and a heavy chain variable domain of AM L 12/AM H 12 (SEQ ID NO:38/SEQ ID NO:12); 
 m. a light chain variable domain and a heavy chain variable domain of AM L 13/AM H 13 (SEQ ID NO:39/SEQ ID NO:13); 
 n. a light chain variable domain and a heavy chain variable domain of AM L 14/AM H 14 (SEQ ID NO:40/SEQ ID NO:14); 
 o. a light chain variable domain and a heavy chain variable domain of AM L 15/AM H 15 (SEQ ID NO:41/SEQ ID NO:15); 
 p. a light chain variable domain and a heavy chain variable domain of AM L 16/AM H 16 (SEQ ID NO:42/SEQ ID NO:16); 
 q. a light chain variable domain and a heavy chain variable domain of AM L 17/AM H 17 (SEQ ID NO:43/SEQ ID NO:17); 
 r. a light chain variable domain and a heavy chain variable domain of AM L 18/AM H 18 (SEQ ID NO:44/SEQ ID NO:18); 
 s. a light chain variable domain and a heavy chain variable domain of AM L 19/AM H 19 (SEQ ID NO:45/SEQ ID NO:19); 
 t. a light chain variable domain and a heavy chain variable domain of AM L 20/AM H 20 (SEQ ID NO:46/SEQ ID NO:20); 
 u. a light chain variable domain and a heavy chain variable domain of AM L 21/AM H 21 (SEQ ID NO:47/SEQ ID NO:21); 
 v. a light chain variable domain and a heavy chain variable domain of AM L 22/AM H 22 (SEQ ID NO:48/SEQ ID NO:22); 
 w. a light chain variable domain and a heavy chain variable domain of AM L 23/AM H 23 (SEQ ID NO: 49 or SEQ ID NO:50/SEQ ID NO:23); 
 x. a light chain variable domain and a heavy chain variable domain of AM L 24/AM H 24 (SEQ ID NO:51/SEQ ID NO:24); 
 y. a light chain variable domain and a heavy chain variable domain of AM L 25/AM H 25 (SEQ ID NO:52/SEQ TD NO:25); and 
 z. a light chain variable domain and a heavy chain variable domain of AM L 26/AM H 26 (SEQ ID NO:53/SEQ ID NO:26); 
 wherein said antibody specifically binds to 1L-17RA. 
   
     
     
         15 . The method according to  claim 14 , wherein said disease state selected from the group consisting of: 
       inflammation, autoimmune disease, cartilage inflammation, and/or bone degradation, arthritis, rheumatoid arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reiter&#39;s Syndrome, SEA Syndrome (Seronegativity, Enthesopathy, Arthropathy Syndrome), juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reiter&#39;s Syndrome, SEA Syndrome (Seronegativity, Enthesopathy, Arthropathy Syndrome), dermatomyositis, psoriatic arthritis, scleroderma, vasculitis, myolitis, polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodossa, Wegener&#39;s granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, scleroderma, sclerosis, primary biliary sclerosis, sclerosing cholangitis, Sjogren&#39;s syndrome, psoriasis, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, dermatitis, atopic dermatitis, atherosclerosis, lupus, Still&#39;s disease, Systemic Lupus Erythematosus (SLE), myasthenia gravis, inflammatory bowel disease (IBD), Crohn&#39;s disease, ulcerative colitis, celiac disease, multiple sclerosis (MS), asthma, COPD, Guillain-Barre disease, Type I diabetes mellitus, Graves&#39; disease, Addison&#39;s disease, Raynaud&#39;s phenomenon, autoimmune hepatitis, and graft versus host disease (GVHD). 
     
     
         16 . The method according to  claim 15 , wherein said disease state is rheumatoid arthritis. 
     
     
         17 . The method according to  claim 15 , wherein said disease state is psoriasis. 
     
     
         18 . The method according to  claim 15 , wherein said disease state is inflammatory bowel disease. 
     
     
         19 . The method according to  claim 15 , further comprising administering to said subject a second treatment comprising a pharmaceutical composition. 
     
     
         20 . The method according to  claim 19 , wherein said second pharmaceutical composition is selected from the group consisting of: TNF inhibitors, soluble TNF receptors, Etanercept, ENBREL®, soluble TNF receptor type-T and soluble TNF receptor type-H, monomeric or multimeric p75 and/or p55 TNF receptor molecules and fragments thereof, anti-TNF antibodies, Infliximab, REMICADE®, D2E7, or HUMIRA®, IL-1 inhibitors, IL-1 receptor inhibitors, CD28 inhibitors, non-steroidal anti-inflammatory drugs (NSAID), a slow acting antirheumatic drugs (SAARD), and disease modifying antirheumatic drugs (DMARD).
Join the waitlist — get patent alerts

Track US2014356355A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.